ClinicalTrials.gg
RecruitingNCT07950501DOTA-1Updated Nov 20, 2026

DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer

An interventional study of Single-fraction MR-guided SBRT 20 Gy with simultaneous integrated boost to the dominant intraprostatic lesion 26 Gy in Prostate Cancer, sponsored by Mahidol University. Recruiting at 1 site in Thailand. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Mahidol University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Prostatic Neoplasms with a site in Thailand — 8 open to participants now, 12 under way, 9 of them phase 3. Prostatic Neoplasms · Thailand.

Planned enrollment
18th of 18
10 · median 800
Started
2026
with 2 others
No phase
2 of 22
2 open now
Primary completion
2027-06
later than 3 of 11 live
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Mahidol University

Among the 22 studies in Prostatic Neoplasms with a site in Thailand, this one is the 18th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 22nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 22 studies in Prostatic Neoplasms with a site in Thailand are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms with a site in Thailand, or all of them as a file.
02

Study summary

This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.

Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure.

The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Stereotactic Ablative Radiotherapy
  • Localized Prostate Cancer
  • Single-fractional SBRT
  • MR-guided Adaptive Radiation Therapy (MRgRT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men ≥ 18 years old
  2. Newly diagnosed and confirmed localized prostate adenocarcinoma
  3. Very low-, low-, and favorable intermediate-risk via NCCN risk group classification, defined as;

    • Gleason grade group 1 or 2
    • Clinical stage T1-T2c
    • Initial PSA \< 20 ng/ml (Patient can have only one of cT2b-cT2c, Gleason grade group 2 and PSA 10-20 ng/ml)
  4. Visible dominant-intraprostatic lesion (DIL) on multi-parametric MRI defined by PI-RADS classification
  5. Performance Status 0-2 within 28 days prior to study entry
  6. Patients must be able to provide study-specific prior to study entry.

Exclusion criteria

Exclusion Criteria:

  1. Direct extraprostatic extension into the adjacent structures
  2. Extraprostatic or malignant nodes
  3. Large prostate volume > 60 cm3 by imaging
  4. Use of Androgen deprivation therapy
  5. Baseline IPSS > 13
  6. MRI- patient (eg., MRI-incompatible pacemaker, metal implant)
  7. Patient with hip prosthesis which causes artifact on MR images
  8. Patient with significant predisposing comorbidity (eg. inflammatory bowel disease)
  9. Prior radiotherapy to the region of the pelvis that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
  10. Prior invasive (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single-fraction MR-guided SBRT

    Radiation: Single-fraction MR-guided SBRT 20 Gy with simultaneous integrated boost to the dominant intraprostatic lesion 26 Gy

Interventions

  • RadiationSingle-fraction MR-guided SBRT 20 Gy with simultaneous integrated boost to the dominant intraprostatic lesion 26 Gy

    A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.

    Also known as: Single-fraction SABR with DIL boost, DOTA-1 regimen

06

What researchers measure

Primary outcomes

  1. Incidence of Acute toxicity (Genitourinary and Gastrointestinal toxicity)

    Incidence of acute treatment-related toxicity from the date of treatment by radiotherapy up to 3 months after completion of radiotherapy, assessed using CTCAE version 5.0

    Time frame: Up to 3 months after SBRT

Secondary outcomes

  1. Incidence of Late toxicity (Genitourinary and Gastrointestinal toxicity)

    Incidence of late (chronic) treatment-related toxicity from 3 months after completion of radiotherapy up to 5 years after completion of radiotherapy, assessed using CTCAE version 5.0

    Time frame: From 3 months to 5 years after SBRT

  2. International Prostate Symptom Score (I-PSS)

    Patient-reported urinary symptoms assessed using the I-PSS. The total score ranges from 0 to 35; higher scores indicate worse urinary symptoms.

    Time frame: Baseline and at each follow-up visit up to 5 years after SBRT

  3. International Index of Erectile Function (IIEF-5) score

    Patient-reported erectile function assessed using the IIEF-5 Score. The total score ranges from 5 to 25; higher scores indicate better erectile function.

    Time frame: Baseline and at each follow-up visit up to 5 years after SBRT

  4. Functional Assessment of Cancer Therapy - Prostate (FACT-P) score

    Health-related quality of life assessed using the FACT-P. The total score ranges from 0 to 156; higher scores indicate better quality of life.

    Time frame: Baseline and at each follow-up visit up to 5 years after SBRT

  5. Freedom from biochemical failure

    Time from SBRT to biochemical failure, defined by the Phoenix criteria (PSA nadir + 2 ng/mL), estimated by the Kaplan-Meier method.

    Time frame: 5 years after SBRT

  6. Local recurrence-free survival

    Time from SBRT to recurrence within the prostate, estimated by the Kaplan-Meier method.

    Time frame: 5 years after SBRT

  7. Overall survival

    Time from SBRT to death from any cause, estimated by the Kaplan-Meier method.

    Time frame: 5 years after SBRT

  8. Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)

    Cost and utility data will be used to evaluate cost-effectiveness by calculating the incremental cost-effectiveness ratio (ICER). Uncertainty analyses will be performed using one-way sensitivity analysis, probabilistic sensitivity analysis, and threshold analysis.

    Time frame: 5 years after SBRT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the study team. The informed consent and ethics approval do not cover data sharing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 20, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2033
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950501
Lead sponsor
Mahidol University
Responsible party
Ratchapas Romrattaphan (Principal Investigator, Siriraj Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Jun 2, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2033 (estimated)
Last update
Nov 20, 2026

Study contacts

Ratchapas Romrattaphan, MD
Contact
ratchapas.rom@gmail.com
+6624197229

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion